Get the Stockscreener App
56.37
4.43%
2.39
Haemonetics Corp stock is traded at $56.37, with a volume of 901.05K.
It is up +4.43% in the last 24 hours and down -24.04% over the past month.
Haemonetics Corp aims to improve patient care and reduce the cost of healthcare by providing medical products and solutions in the blood and plasma component collection, surgical suite, and hospital transfusion service spaces. As such, the company operates under three segments: plasma, blood center, and hospital. The company primarily emphasizes its plasma and hospital segments due to their robust growth potential, whereas the blood center segment tends to be constrained by higher competition. Product revenue is driven by demand for disposable blood component collection and processing sets and the related equipment needed for proper functionality.
See More
Previous Close:
$53.98
Open:
$54.19
24h Volume:
901.05K
Relative Volume:
1.27
Market Cap:
$2.72B
Revenue:
$1.36B
Net Income/Loss:
$123.81M
P/E Ratio:
23.39
EPS:
2.41
Net Cash Flow:
$20.35M
1W Performance:
+4.89%
1M Performance:
-24.04%
6M Performance:
-10.55%
1Y Performance:
-25.34%
1-Day Range:
$54.12
$56.64
1-Week Range:
$53.01
$56.64
52-Week Range:
$50.68
$94.98
Haemonetics Corp Stock (HAE) Company Profile
Name
Haemonetics Corp
Sector
Industry
Phone
(781) 848-7100
Address
125 SUMMER STREET, BOSTON, MA
Compare HAE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HAE
Haemonetics Corp
|
56.37 | 2.56B | 1.36B | 123.81M | 20.35M | 2.41 |
|
ABT
Abbott Laboratories
|
132.59 | 226.73B | 43.11B | 13.94B | 6.78B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.17 | 152.69B | 18.49B | 2.50B | 3.49B | 1.68 |
|
SYK
Stryker Corp
|
394.22 | 145.89B | 23.82B | 2.92B | 4.02B | 7.55 |
|
MDT
Medtronic Plc
|
92.71 | 118.91B | 33.54B | 4.69B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
81.83 | 45.97B | 5.69B | 1.41B | 577.90M | 6.95 |
Haemonetics Corp Stock (HAE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-11-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| Aug-08-25 | Reiterated | Barrington Research | Outperform |
| Aug-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-09-25 | Upgrade | Citigroup | Neutral → Buy |
| Jun-26-25 | Initiated | Robert W. Baird | Outperform |
| Feb-07-25 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-06-24 | Initiated | JP Morgan | Overweight |
| Nov-08-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-13-24 | Initiated | CL King | Buy |
| Sep-11-24 | Initiated | BofA Securities | Neutral |
| Sep-10-24 | Initiated | BTIG Research | Buy |
| Jun-12-24 | Upgrade | Needham | Hold → Buy |
| Oct-13-22 | Initiated | Mizuho | Buy |
| Jan-27-22 | Downgrade | Needham | Buy → Hold |
| Dec-15-21 | Downgrade | Citigroup | Buy → Neutral |
| Aug-17-21 | Resumed | Raymond James | Outperform |
| Jun-17-21 | Initiated | Citigroup | Buy |
| May-14-21 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Apr-20-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-19-21 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Feb-03-21 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jan-21-21 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-05-20 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| May-06-20 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Mar-31-20 | Upgrade | CJS Securities | Market Perform → Market Outperform |
| Jan-10-20 | Initiated | Needham | Buy |
| Aug-07-19 | Reiterated | Barrington Research | Outperform |
| May-14-19 | Upgrade | Raymond James | Mkt Perform → Outperform |
| May-08-19 | Reiterated | Barrington Research | Outperform |
| Aug-09-18 | Reiterated | Barrington Research | Outperform |
| Feb-07-18 | Reiterated | Barrington Research | Outperform |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-08-17 | Reiterated | Barrington Research | Outperform |
| Aug-08-17 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Jul-13-17 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Feb-07-17 | Downgrade | Barrington Research | Outperform → Mkt Perform |
| Nov-08-16 | Upgrade | Barrington Research | Mkt Perform → Outperform |
| Nov-07-16 | Reiterated | The Benchmark Company | Hold |
| Sep-20-16 | Downgrade | CJS Securities | Market Outperform → Market Perform |
| Aug-15-16 | Downgrade | Sidoti | Buy → Neutral |
| Aug-02-16 | Reiterated | Jefferies | Buy |
| Aug-02-16 | Reiterated | The Benchmark Company | Hold |
View All
Haemonetics Corp Stock (HAE) Latest News
Quantitative breakdown of Haemonetics Corporation recent moveEarnings Risk Summary & Real-Time Price Movement Reports - Newser
Can Haemonetics Corporation hit a new high this monthEarnings Risk Report & Detailed Earnings Play Strategies - Newser
Full technical analysis of Haemonetics Corporation stockEarnings Miss & Fast Gain Stock Trading Tips - Newser
Can a trend reversal in Haemonetics Corporation lead to recoveryEarnings Growth Report & Pattern Based Trade Signal System - Newser
Can machine learning forecast Haemonetics Corporation recoveryAnalyst Upgrade & Stock Market Timing Techniques - Newser
Technical Charts Suggest Momentum Shift in Haemonetics CorporationWeekly Risk Summary & Low Risk High Reward Ideas - thegnnews.com
How to escape a deep drawdown in Haemonetics CorporationMarket Performance Report & Verified Short-Term Plans - Newser
Vanguard Group Inc. Has $324.08 Million Stake in Haemonetics Corporation $HAE - Defense World
Should you hold or exit Haemonetics Corporation nowQuarterly Market Review & Risk Managed Investment Strategies - Newser
What makes Haemonetics Corporation stock attractive to long term investorsFed Meeting & Daily Oversold Bounce Ideas - Newser
Analyzing net buyer seller activity in Haemonetics CorporationJuly 2025 WrapUp & Verified Chart Pattern Signals - Newser
PNC Financial Services Group Inc. Has $294,000 Stock Holdings in Haemonetics Corporation (NYSE:HAE) - Defense World
Will Haemonetics Corporation see short term momentum2025 Major Catalysts & Reliable Entry Point Trade Alerts - Newser
Is Haemonetics Corporation stock entering bullish territory2025 Technical Overview & Stepwise Swing Trade Plans - Newser
Is Haemonetics Corporation meeting your algorithmic filter criteriaJuly 2025 Weekly Recap & Technical Buy Zone Confirmations - Newser
Haemonetics Corporation stock outlook for YEAR2025 Retail Activity & High Yield Stock Recommendations - Newser
Patient Blood Management Market Growth Analysis Report 2025-2033 | AI-Driven Analytics Revolutionize Blood Management Strategies, Blockchain Enhances Supply Transparency and Safety - GlobeNewswire Inc.
Mizuho lowers Haemonetics stock price target to $70 on VASCADE MVP slowdown - Investing.com Nigeria
The Top 5 Analyst Questions From Haemonetics’s Q2 Earnings Call - Yahoo Finance
Advanced analytics toolkit walkthrough for Haemonetics CorporationQuarterly Portfolio Review & High Conviction Trade Alerts - Newser
Haemonetics Corporation Shows Support at Fibonacci Level2025 Buyback Activity & Fast Entry High Yield Tips - metal.it
Haemonetics (NYSE:HAE) Rating Lowered to Outperform at Raymond James Financial - Defense World
Haemonetics Corporation (NYSE:HAE) Q1 2026 Earnings Call Transcript - Insider Monkey
I’m Recommending Haemonetics Again, But With Caveats (Ratings Upgrade) (NYSE:HAE) - Seeking Alpha
Haemonetics Corporation shares fall 2.69% intraday after Raymond James downgrades to Outperform. - AInvest
Understanding Haemonetics (HAE) Reliance on International Revenue - Yahoo Finance
Haemonetics stock rating downgraded by Raymond James on vascular closure slowdown - Investing.com
Haemonetics’ (HAE) “Neutral” Rating Reiterated at JPMorgan Chase & Co. - Defense World
Mizuho Issues Pessimistic Forecast for Haemonetics (NYSE:HAE) Stock Price - Defense World
Haemonetics (NYSE:HAE) Price Target Cut to $68.00 by Analysts at Needham & Company LLC - Defense World
Barrington Research Lowers Haemonetics (NYSE:HAE) Price Target to $86.00 - Defense World
Haemonetics’ (HAE) Buy Rating Reiterated at Needham & Company LLC - Defense World
A Quick Look at Today's Ratings for Haemonetics(HAE.US), With a Forecast Between $62 to $86 - 富途牛牛
Detecting price anomalies in Haemonetics Corporation with AIFree Trade Ready Stock Watch for Short Term - Newser
What makes Haemonetics Corporation stock price move sharplyAI Swing Strategy Signal Forecasting System - Newser
Haemonetics Reports Q1 Fiscal 2026 Earnings - The Globe and Mail
JP Morgan Downgrades Haemonetics (HAE) - MSN
Haemonetics Corporation stock trendline breakdownFree Breakout Confirmation With Entry Tracker - Newser
Haemonetics Corp Reports Strong Organic Growth Despite Portfolio Transitions - AInvest
These Analysts Slash Their Forecasts On Haemonetics After Q1 Results - Benzinga
Haemonetics (HAE): Mizuho Lowers Price Target to $70.00 While Ma - GuruFocus
This Trade Desk Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday - Benzinga
Technical signs of recovery in Haemonetics CorporationSummary of Consistent Growth Stock Picks - Newser
A Glimpse Into The Expert Outlook On Haemonetics Through 6 Analysts - 富途牛牛
Haemonetics: Fiscal Q1 Earnings Snapshot - Connecticut Post
Haemonetics stock rating cut by JPMorgan on mixed results - Investing.com
Haemonetics (NYSE:HAE) Shares Down 22.1% Following Analyst Downgrade - Defense World
Haemonetics' Q1 2026 Earnings Call: Key Contradictions in Plasma Growth, Margins, and Competitive Strategy - AInvest
Decoding Haemonetics Corp (HAE): A Strategic SWOT Insight - GuruFocus
Haemonetics Corp (HAE) Analysts Lower Price Target to $68, Maintain "Buy" Rating - AInvest
Haemonetics (NYSE:HAE) Surprises With Strong Q2 But Stock Drops 24% - Yahoo Finance
Haemonetics Corp Stock (HAE) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.89%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):